Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 23;7(8):e736.
doi: 10.1097/TXD.0000000000001190. eCollection 2021 Aug.

Clinical Correlates and Outcomes of Dual Basiliximab and Antithymocyte Globulin Induction in Kidney Transplant Recipients: A National Study

Ngan N Lam  1 , Rachel Jeong  1 , Robert R Quinn  1 , Pietro Ravani  1 , Huiling Xiao  2 , Mara McAdams-DeMarco  3 , David A Axelrod  4 , Mark A Schnitzler  2 , Jon J Snyder  5 , Krista L Lentine  2
Affiliations

Clinical Correlates and Outcomes of Dual Basiliximab and Antithymocyte Globulin Induction in Kidney Transplant Recipients: A National Study

Ngan N Lam et al. Transplant Direct. .

Abstract

The unplanned use of dual induction therapy with interleukin-2 receptor-blocking antibodies (IL2rAb) and antithymocyte globulin (ATG) may portend adverse outcomes.

Methods: We used national transplant registry data to study clinical correlates and outcomes of single versus dual induction therapy in adult kidney-only transplant recipients in the United States (2005-2018). The risk of death and graft loss at 1 and 5 y, according to induction therapy type, was assessed using multivariate Cox regression analysis (adjusted hazard ratio with 95% upper and lower confidence limits [LCLaHRUCL]).

Results: Of the 157 351 recipients included in the study, 67% were treated with ATG alone, 29% were treated with IL2rAb alone, and 5% were treated with both. Compared with IL2rAb alone, the strongest correlates of dual induction included Black race, calculated panel reactive antibody ≥80%, prednisone-sparing maintenance immunosuppression, more recent transplant eras, longer cold ischemia time, and delayed graft function. Compared with ATG alone, dual induction was associated with an increased 5-y risk of death (aHR 1.071.151.23; P < 0.0001), death-censored graft failure (aHR 1.051.131.22; P < 0.05), and all-cause graft failure (aHR 1.061.121.18; P < 0.0001).

Conclusions: Further research is needed to develop risk-prediction tools to further inform optimal, individualized induction protocols for kidney transplant recipients.

PubMed Disclaimer

Conflict of interest statement

K.L.L. serves on the Sanofi-Genzyme speakers bureau. D.A.A. is a consultant to Sanofi-Genzyme. The other authors declare no conflicts of interest.

Figures

FIGURE 1.
FIGURE 1.
Induction therapy regimen overall and by recipient immunologic risk profile, wherein high risk was defined as Black race, cPRA ≥80%, or retransplant. *P < 0.05–0.002; †P=0.001–0.0001; ‡P < 0.0001. ATG, antithymocyte globulin; IL2rAb, interleukin-2 receptor-blocking antibodies; cPRA, calculated panel reactive antibody.
FIGURE 2.
FIGURE 2.
National trends in kidney transplant induction over time. ATG, antithymocyte globulin; IL2rAb, interleukin-2 receptor-blocking antibodies.
FIGURE 3.
FIGURE 3.
Kaplan-Meier cumulative incidence of death and graft failure according to type of induction therapy at (A) 1 y posttransplant and (B) 5 y posttransplant. *P < 0.05–0.002; †P=0.001–0.0001; ‡P < 0.0001. ACGF, all-cause graft failure; ATG, antithymocyte globulin; DCGF, death-censored graft failure; IL2rAb, interleukin-2 receptor-blocking antibodies.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9(suppl 3):S1–S155. - PubMed
    1. Webster AC, Ruster LP, McGee RG, et al. . Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev. 2010;1:CD003897. - PMC - PubMed
    1. Jeong R, Quinn RR, Lentine KL, et al. . Incidence, risk factors, and outcomes of kidney transplant recipients treated with both basiliximab and antithymocyte globulin. Can J Kidney Health Dis. 2020;7:1–12. - PMC - PubMed
    1. Dharnidharka VR, Naik AS, Axelrod DA, et al. . Center practice drives variation in choice of US kidney transplant induction therapy: a retrospective analysis of contemporary practice. Transpl Int. 2018;31:198–211. - PMC - PubMed
    1. Brennan DC, Daller JA, Lake KD, et al. ; Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006;355:1967–1977. - PubMed